View Post

TGen-led study results suggest more accurate diagnostic for breast cancer

In Clinical Trials by Barbara Jacoby

Source: The Translational Genomics Research Institute From: eurekalert.org Breast cancer, even at its initial stages, could be detected earlier and more accurately than current techniques using blood samples and a unique proteomics-based technology, according to findings of a study led by the Translational Genomics Research Institute (TGen), an affiliate of City of Hope. Patrick Pirrotte, Ph.D., an Assistant Professor and …

View Post

Paper Conversation Aids Are Helpful in Improving Outcomes for Lower Socioeconomic Status Breast Cancer Patients

In Clinical Trials by Barbara Jacoby

By: Kaitlyn D’Onofrio From: docwirenews.com Using paper conversation aids when speaking with women of lower socioeconomic status (SES) with breast cancer improved outcomes compared to usual care alone, according to a study. “Conversation aids increase patients’ knowledge and participation in decision making and improve risk perceptions without increasing the visit duration. They can be integrated into routine care and electronic …

View Post

Identification of Tamoxifen Resistance Markers Can Play Role in Breast Cancer Treatment Planning

In Clinical Trials by Barbara Jacoby

By: Rutgers Cancer Institute of New Jersey From: newswise.com One common challenge of cancer therapy is when cancer cells don’t respond to a drug that is usually able to kill or weaken them, known as treatment resistance. Tamoxifen is a drug that blocks the activity of estrogen in the breast, commonly used to treat patients with estrogen-receptor (ER) positive breast cancer. In …

View Post

Study updates breast cancer risk estimates for women with no family history

In Clinical Trials by Barbara Jacoby

Source: Mayo Clinic From: eurekalert.org A new multi-institution study led by Fergus Couch, Ph.D., a Mayo Clinic pathologist, provides more accurate estimates of breast cancer risk for U.S. women who harbor inherited mutations in breast cancer predisposition genes. The findings of the CARRIERS Consortium study, which were published Wednesday, Jan. 20 in the New England Journal of Medicine, may allow …

View Post

NCCN Now Recommends Breast Cancer Index for Predicting Benefit from Extended Endocrine Therapy

In Clinical Trials by Barbara Jacoby

By: Audrey Sternberg From: cancernetwork.com The Breast Cancer Index assay is the only of its kind to be recommended in the National Comprehensive Cancer Network Guidelines for the treatment of breast cancer as being predictive of extended adjuvant endocrine therapy. Breast Cancer Index (BCI), a molecular gene expression–based test used for determining which patients with early-stage, hormone receptor (HR)–positive breast …

View Post

Mental Illness May Predispose Women With Breast Cancer to Higher Mortality

In Clinical Trials by Barbara Jacoby

By: Maggie L. Shaw From: ajmc.com Severe mental illnesses that precede a breast cancer diagnosis may increase the risk of both all-cause and cancer-specific mortality among women with Medicaid coverage, according to research findings recently published in Social Science & Medicine. By linking Medicaid diagnosis claims for preexisting depression or severe mental illness (SMI; schizophrenia, bipolar disorder, other psychotic disorders) …

View Post

CairnSurgical Announces First Patient Treated in Pivotal Clinical Trial of Breast Cancer Locator System

In Clinical Trials by Barbara Jacoby

From: businesswire.com CairnSurgical, Inc., an innovator striving to make breast cancer surgery more precise, announced today that the first patient has been treated in its U.S. pivotal trial of the Breast Cancer Locator (BCL) System at Massachusetts General Hospital. The BCL System is designed to eliminate guesswork in breast cancer surgery by providing a blueprint of the tumor and a …

View Post

Breast Cancer Risk Gene Associations Refined in Large-Scale Studies

In Clinical Trials by Barbara Jacoby

By: Staff Reporter From: precisiononcologynews.com Studies by two independent research teams are offering a clearer picture of the germline pathogenic variants that contribute to breast cancer risk, suggesting that some risk genes may be linked to specific breast cancer subtypes, while others are more broadly associated with breast cancer. For one study, published on Wednesday in the New England Journal …

View Post

Seven-year Data Shows Accuray TomoTherapy® System Provides Excellent Long-Term Control of Low-Risk Breast Cancer

In Clinical Trials by Barbara Jacoby

Source: Accuray Incorporated From: prnewswire.com Advanced, 10-Day Radiation Treatment Regimen Enables Patients to Get Back to Their Life, Faster Accuray Incorporated (NASDAQ: ARAY) announced today that data from a prospective, phase II trial of 338 women with low-risk breast cancer showed 98.8 percent had local disease control seven years after receiving once-daily accelerated partial breast irradiation (APBI) delivered with the …

View Post

Dual Aromatase-Sulphatase Inhibitors (DASIs) for the Treatment of Hormone Dependent Breast Cancer

In Clinical Trials by Barbara Jacoby

From: docwirenews.com ABSTRACT Breast cancer is the most frequent diagnosed cancer in women and the second most common form of cancer, causing death after lung cancer, all across the globe at an alarming rate. The level of estrogens, in breast cancer tissues of postmenopausal women is 10-40 folds higher than the non-carcinogenic breast tissues. As a result of this greater …